GLPwatch

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

NCT06851962 · Active, not recruiting

Last updated 2026-05-28

This clinical trial compares whether using genetic testing to guide diabetes treatment helps more people with type 2 diabetes reach their blood sugar target within 24 weeks compared to standard treatment.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design Randomized, single-blind treatment study
Participants 504 people Planned (estimated).
Who can join Ages 40–70 · all sexes
Timeline Started 2025-05 · est. completion 2026-06
Where 3 sites · Spain

What this study is testing ClinicalTrials.gov NCT06851962 ↗

Description as written by the study sponsor.

The goal of this clinical trial is to assess the efficacy of a pharmacogenetics-guided treatment, compared to standard optimized treatment, in patients with inadequately controlled type 2 diabetes. The main questions it aims to answer are: * Is the disease better controlled when the treatment prescribed is based on the participant's pharmacogenetic profile? * What medical problems do participants experience while taking the treatment? Participants will: * Take the treatment described according to the Summary of Product Characteristics (SmPC). * Visit the clinic once every 12 weeks for checkups and tests. * Keep a diary of their symptoms to inform the Investigator.

Treatments tested

Main thing measuredComparison of HbA1c ≤7% goal at Week 24 between Pharmacogenetic-Guided and Standard Treatment in Type 2 Diabetes
SponsorFundación para la Investigación del Hospital Clínico de Valencia
Conditions studiedDiabetes Mellitus Type 2
GLP-1 drugs —

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06851962 ↗